ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+17.60%Oct 16, 2026, 21:34 UTC
Annexon granted inducement awards to six new non-executive employees under its 2022 Employment Inducement Award Plan.
Source:Sep 24, 2026, 12:00 UTC
Annexon, Inc. announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting in Los Angeles, presenting patient baseline characteristics from the Phase 3 ARCHER II pivotal trial for geographic atrophy.
Source:Sep 16, 2026, 20:05 UTC
Annexon granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026, per Nasdaq Listing Rule 5635(c)(4).
Source:Aug 12, 2026, 10:00 UTC
Annexon announced the launch of an open-label extension study of vonaprument for geographic atrophy, and added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial.
Aug 12, 2026, 00:00 UTC
Annexon, Inc. reported its Q2 2026 financial results, with a net loss of $55.3 million and diluted EPS of -$0.28, and cash and investments of $209.2 million as of June 30, 2026.
Source:Jul 30, 2026, 20:01 UTC
Annexon secured a strategic credit facility for up to $200 million from Oxford Finance.
Source: